α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

Alpha Synuclein: New Species – The Science of Parkinson's

Calcipotriol inhibits α‐synuclein aggregation in SH‐SY5Y neuroblastoma cells by a Calbindin‐D28k‐dependent mechanism - Rcom‐H'cheo‐Gauthier - 2017 - Journal of Neurochemistry - Wiley Online Library

IJMS, Free Full-Text

Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway

Pathological pathway of α-synuclein aggregation. Abnormal misfolded

α-Synuclein aggregation process (α-syn, principal constituent of

Parkinson's Study Finds New Compound that Can Inhibit Alpha-Synuclein

Brain-Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha-Synuclein Aggregation and Improve Behavioral Symptoms of Parkinson's Disease - Pharma Excipients

Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction

Targeting Alpha-Synuclein in the Gut May Slow Down Parkinson's Disease

α-Synuclein Aggregation in Treatment of Parkinson's Disease

Alpha Synuclein Assay